Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/124842
Title: Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer
Author: Gonzalo, Victoria
Lozano Salvatella, Juan José
Muñoz, Jenifer
Balaguer Prunés, Francesc
Pellisé Urquiza, Maria
Rodríguez de Miguel, Cristina
Andreu, Montserrat
Jover, Rodrigo
Llor, Xavier
Giraldez, M. Dolores
Ocaña, Teresa
Serradesanferm, Anna
Alonso-Espinaco, Virginia
Jimeno, Mireya
Cuatrecasas Freixas, Miriam
Sendino, Oriol
Castellví-Bel, Sergi
Castells Garangou, Antoni
Keywords: Càncer colorectal
Genètica humana
Metilació
ADN
Colorectal cancer
Human genetics
Methylation
DNA
Issue Date: 19-Jan-2010
Publisher: Public Library of Science (PLoS)
Abstract: Background Colorectal cancer (CRC) multiplicity has been mainly related to polyposis and non-polyposis hereditary syndromes. In sporadic CRC, aberrant gene promoter methylation has been shown to play a key role in carcinogenesis, although little is known about its involvement in multiplicity. To assess the effect of methylation in tumor multiplicity in sporadic CRC, hypermethylation of key tumor suppressor genes was evaluated in patients with both multiple and solitary tumors, as a proof-of-concept of an underlying epigenetic defect. Methodology/Principal Findings We examined a total of 47 synchronous/metachronous primary CRC from 41 patients, and 41 gender, age (5-year intervals) and tumor location-paired patients with solitary tumors. Exclusion criteria were polyposis syndromes, Lynch syndrome and inflammatory bowel disease. DNA methylation at the promoter region of the MGMT, CDKN2A, SFRP1, TMEFF2, HS3ST2 (3OST2), RASSF1A and GATA4 genes was evaluated by quantitative methylation specific PCR in both tumor and corresponding normal appearing colorectal mucosa samples. Overall, patients with multiple lesions exhibited a higher degree of methylation in tumor samples than those with solitary tumors regarding all evaluated genes. After adjusting for age and gender, binomial logistic regression analysis identified methylation of MGMT2 (OR, 1.48; 95% CI, 1.10 to 1.97; p = 0.008) and RASSF1A (OR, 2.04; 95% CI, 1.01 to 4.13; p = 0.047) as variables independently associated with tumor multiplicity, being the risk related to methylation of any of these two genes 4.57 (95% CI, 1.53 to 13.61; p = 0.006). Moreover, in six patients in whom both tumors were available, we found a correlation in the methylation levels of MGMT2 (r = 0.64, p = 0.17), SFRP1 (r = 0.83, 0.06), HPP1 (r = 0.64, p = 0.17), 3OST2 (r = 0.83, p = 0.06) and GATA4 (r = 0.6, p = 0.24). Methylation in normal appearing colorectal mucosa from patients with multiple and solitary CRC showed no relevant difference in any evaluated gene. Conclusions These results provide a proof-of-concept that gene promoter methylation is associated with tumor multiplicity. This underlying epigenetic defect may have noteworthy implications in the prevention of patients with sporadic CRC.
Note: Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0008777
It is part of: PLoS One, 2010, vol. 5, num. 1, p. e8777
URI: http://hdl.handle.net/2445/124842
Related resource: https://doi.org/10.1371/journal.pone.0008777
ISSN: 1932-6203
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
635286.pdf204.59 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons